Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine

Table 5 Effects of 26-week treatment of exenatide versus insulin glargine on imaging parameters

	Exenatide (n = 11)			Insulin glargine (n = 12)			P between groups
	Baseline	Follow-up	P	Baseline	Follow-up	P	Baseline	Follow-up
CMR
LVEDV, mL	176 ± 42	175 ± 31	0.90	206 ± 38	206 ± 44	0.93	0.10	0.49
LVESV, mL	86 ± 26	86 ± 25	1.00	104 ± 29	109 ± 31	0.11	0.13	0.25
LV mass, g	110 ± 29	105 ± 20	0.31	113 ± 23	118 ± 23	0.27	0.82	0.05
LVEF, %	51 ± 7	52 ± 7	0.85	50 ± 9	47 ± 10	0.06	0.58	0.11
DCE, g	9.5 (1.0–11.4)	8.8 (2.2–14.0)	0.74	10.5 (5.8–21.7)	14.1 (5.3–27.4)	0.07	0.33	0.17
PET
MBF, rest, mL min⁻¹ g⁻¹	0.92 ± 0.18	0.86 ± 0.11	0.33	0.80 ± 0.18	0.86 ± 0.17	0.31	0.15	0.57
MBF, rest, corrected for RPP, mL min⁻¹ g⁻¹	1.25 ± 0.46	1.03 ± 0.26	0.04	1.02 ± 0.26	0.98 ± 0.16	0.59	0.16	0.45
MBF, stress, mL min⁻¹ g⁻¹	2.29 ± 0.53	2.20 ± 0.59	0.57	2.00 ± 0.68	1.94 ± 0.62	0.46	0.28	0.79
CFR	2.59 ± 0.82	2.60 ± 0.89	0.96	2.51 ± 0.72	2.24 ± 0.59	0.20	0.82	0.22
CFR, corrected for RPP, mmHg min⁻¹	2.03 ± 0.76	2.26 ± 0.79	0.19	2.04 ± 0.77	1.98 ± 0.62	0.65	0.96	0.16
External work, Joule	1.06 ± 0.38	0.98 ± 0.20	0.35	1.12 ± 0.34	1.12 ± 0.34	0.99	0.70	0.21
MVO₂, mL g⁻¹ min⁻¹	0.08 ± 0.01	0.08 ± 0.01	0.52	0.08 ± 0.01	0.07 ± 0.02	0.23	0.28	0.48
Myocardial efficiency, %	36 ± 8	38 ± 6	0.53	39 ± 8	40 ± 11	0.59	0.45	0.84

Data are mean ± SD or median (interquartile range). CMR cardiac magnetic resonance
LVEDV left ventricular enddiastolic volume, LVESV left ventricular endsystolic volume, LVEF left ventricular ejection fraction, DCE delayed contrast enhancement, PET positron emission tomography, MBF myocardial blood flow, RPP rate pressure product, CFR coronary flow reserve, MVO2 myocardial oxygen consumption

ISSN: 1475-2840